Epigenetics Stocks

Precision biopharmaceutical and diagnostic entities in this sector target the regulatory layer of the genome to control gene expression without altering the underlying DNA sequence.

As of Oct 23, 2026, Epigenetics has 5 US-listed companies worth $399M combined. The median member moved +0.0% over the past week; FHTX led at +8.1% and FOXO trailed at -9.1%.